Lucid Diagnostics (LUCD) Net Cash Flow Growth (3y) (2023 - 2026)
Lucid Diagnostics (LUCD) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -87.88% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 129.29% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -48.90% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -65.12% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Lucid Diagnostics | 133.09 Mn | 105.22 Mn | -325,000.00 | -33.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.90% |
| Dec 31, 2025 | -41.49% |
| Sep 30, 2025 | 68.95% |
| Jun 30, 2025 | 33.63% |
| Mar 31, 2025 | 35.76% |
| Dec 31, 2024 | -47.26% |
| Sep 30, 2024 | -67.74% |
| Jun 30, 2024 | -58.70% |
| Mar 31, 2024 | 527.18% |
| Dec 31, 2023 | -308.71% |